Outcomes of HIFU for localised prostate cancer using the Ablatherm Integrate Imaging® device;Traitement du cancer localisé de la prostate avec l'appareil Ablatherm Imagerie Intégrée

Progres en Urologie

Volumn 21, Issue 3, 2011, Pages 191-197

  Crouzet, S ^a,b   Poissonnier, L ^a   Murat, F J ^c   Pasticier, G ^d   Rouviere O ^a   Mege Lechevallier F ^a   Chapelon, J Y ^b   Martin, X ^a   Gelet, A ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c Clinique du Val d'Ouest   (France)

^d HÔPITAL PELLEGRIN   (France)

Author keywords

Ablatherm; Cancer; Functional outcomes; HIFU; Prostate; Quality of life; Side effect

Indexed keywords

AGED; ARTICLE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; PROSPECTIVE STUDY; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 79952007544     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2010.07.005     Document Type: Article

References (20)

1. Bill-Axelson A., Holmberg L., Filen F., Ruutu M., Garmo H., Busch C., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008, 100:1144-1154.
2. Zelefsky M.J., Reuter V.E., Fuks Z., Scardino P., Shippy A. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008, 179:1368-1373. [discussion 73].
3. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol;28:126-31.
4. Poissonnier L., Murat F.J., Belot A., Bouvier R., Rabilloud M., Rouviere O., et al. Locally recurrent prostatic adenocarcinoma after exclusive radiotherapy: results of high intensity focused ultrasound. Prog Urol 2008, 18:223-229.
5. Pichardo S., Gelet A., Curiel L., Chesnais S., Chapelon J.Y. New integrated imaging high intensity focused ultrasound probe for transrectal prostate cancer treatment. Ultrasound Med Biol 2008, 34:1105-1116.
6. Chaussy C., Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003, 4:248-252.
7. Vallancien G., Prapotnich D., Cathelineau X., Baumert H., Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004, 171:2265-2267.
8. Uchida T., Illing R.O., Cathcart P.J., Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?. BJU Int 2006, 98:537-539.
9. Ganzer R., Rogenhofer S., Walter B., Lunz J.C., Schostak M., Wieland W.F., et al. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 2008, 53:547-553.
10. Blana A., Brown S.C., Chaussy C., Conti G.N., Eastham J.A., Ganzer R., et al. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009, 104:1058-1062.
11. Blana A., Rogenhofer S., Ganzer R., Wild P.J., Wieland W.F., Walter B. Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006, 24:585-590.
12. Rouviere O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mege-Lechevallier F, et al. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol;20:48-55.
13. Pollack A., Zagars G.K., Antolak J.A., Kuban D.A., Rosen I.I. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002, 54:677-685.
14. Zapatero A., Minguez R., Nieto S., Martin de Vidales C., Garcia-Vicente F. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?. Eur Urol 2009, 55:902-909.
15. Pollack A., Hanlon A., Horwitz E.M., Feigenberg S., Uzzo R.G., Price R.A. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol 2003, 21:200-208.
16. Kuban D.A., Tucker S.L., Dong L., Starkschall G., Huang E.H., Cheung M.R., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
17. Pasticier G., Chapet O., Badet L., Ardiet J.M., Poissonnier L., Murat F.J., et al. Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Urology 2008, 72:1305-1309.
18. Rouviere O, Vitry T, Lyonnet D. Imaging of prostate cancer local recurrences: why and how? Eur Radiol;20:1254-66.
19. Sanda M.G., Dunn R.L., Michalski J., Sandler H.M., Northouse L., Hembroff L., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
20. Rassweiler J., Teber D., Kuntz R., Hofmann R. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol 2006, 50:969-979. [discussion 80].